Br J Cancer. 1981 Nov;44(5):611-7. doi: 10.1038/bjc.1981.245.
This report compares the results at 36 months for 121 patients treated with radiotherapy alone (R) and 115 with radiotherapy followed by 3-drug chemotherapy (RC) for small-cell carcinoma of the lung of "limited" extent. The RC patients had an increased survival (P = 0.009 by log-rank test). The median survival was 25 weeks for the R patients and 43 weeks for the RC patients, but at 36 months, only 4 (3%) of the R patients and 5 (4%) of the RC patients were still alive. There was evidence of recurrence of the primary cancer in 41 (35%) of the 117 R and 35 (32%) of the 110 RC patients who died. Distant metastases were more frequent in the R series, being reported in 99 (82%) compared with 82 (71%) of the RC patients (P less than 0.05 by log-rank test). The numbers of R patients alive and considered free of metastases were 10 (8%) at 12 months, 3 (2%) at 24 months and 3 (2%) at 36 months; the corresponding figures for the RC patients being 30 (26%), 9 (8%), and 4 (3%).
本报告比较了121例仅接受放疗（R）和115例接受放疗后进行三联化疗（RC）的“局限期”小细胞肺癌患者36个月时的结果。接受RC治疗的患者生存率有所提高（对数秩检验P = 0.009）。R组患者的中位生存期为25周，RC组患者为43周，但在36个月时，R组仅4例（3%）患者存活，RC组为5例（4%）。在117例死亡的R组患者中有41例（35%）以及110例死亡的RC组患者中有35例（32%）出现原发性癌症复发迹象。远处转移在R组中更常见，R组有99例（82%）报告有远处转移，而RC组为82例（71%）（对数秩检验P<0.05）。R组存活且被认为无转移的患者数量在12个月时为10例（8%），24个月时为3例（2%），36个月时为3例（2%）；RC组相应的数据分别为30例（26%）、9例（8%）和4例（3%）。
